Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sartorius AG (SRT3.DE)
Göttingen, DE
Sartorius AG is a global supplier of advanced bioprocess and laboratory solutions, offering a comprehensive portfolio of products and services essential for life science research and biopharmaceutical manufacturing. The company's offerings include sophisticated biosensors and detection systems, live-cell analysis platforms, and a wide array of cell culture media and reagents. Sartorius also manufactures various bioreactors, ranging from benchtop to large-scale single-use and stainless steel systems, along with their associated software applications. Its extensive filtration product line encompasses membranes, specialized filters, and diverse devices for ultrafiltration, sterile filtration, and sample preparation. Furthermore, Sartorius provides process chromatography and fluid management solutions, industrial microbiology systems, water purification units, and essential lab equipment such as weighing, pipetting, and centrifugation systems. Beyond products, the company delivers critical services including bioprocess development, protein expression, and validation. Serving sectors like life science research, biopharmaceutical manufacturing, and quality control, Sartorius was established in 1870 and is headquartered in Göttingen, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.13% | +5.42% | +12.85% | +2.00% | -2.43% | -1.09% | +19.56% | -21.82% | -39.48% | +294.94% | +16,131.79% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | -1 |
| Buy | 10 | 0 |
| Hold | 6 | -1 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+4.7% Q1'26: +1.8% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+83.6% ★ Q1'26: +15.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+9.9% Q1'26: +11.0% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+18.4% ★ Q1'26: +16.8% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+5.7% Q1'26: +5.8% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.1% Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×4.16× Q1'26: 4.17× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 22 Rev. Ana. 9 EPS Ana. |
Dec 2027 22 Rev. Ana. 15 EPS Ana. |
Dec 2028 19 Rev. Ana. 9 EPS Ana. |
Dec 2029 10 Rev. Ana. 3 EPS Ana. |
Dec 2030 16 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.11B
est: 1.12B (-0.2%)
|
1.30B
est: 1.30B (-0.1%)
|
1.40B
est: 1.41B (-0.3%)
|
1.57B
est: 1.57B (+0.0%)
|
1.83B
est: 1.81B (+0.7%)
|
2.34B
est: 2.31B (+1.3%)
|
3.45B
est: 3.40B (+1.5%)
|
4.17B
est: 4.14B (+0.8%)
|
3.40B
est: 3.34B (+1.6%)
|
3.38B
est: 3.36B (+0.7%)
|
3.54B
est: 3.54B (-0.1%)
|
3.74B
3.68B – 3.95B
+5.7% YoY
|
4.10B
3.99B – 4.27B
+9.5% YoY
|
4.50B
4.50B – 4.51B
+9.9% YoY
|
4.93B
4.82B – 5.17B
+9.4% YoY
|
5.40B
5.28B – 5.66B
+9.5% YoY
|
| EBITDA |
252.59M
est: 314.60M (-19.7%)
|
297.21M
est: 366.54M (-18.9%)
|
326.22M
est: 396.57M (-17.7%)
|
409.18M
est: 440.81M (-7.2%)
|
463.53M
est: 510.75M (-9.2%)
|
662.13M
est: 649.42M (+2.0%)
|
945.12M
est: 957.04M (-1.2%)
|
1.50B
est: 1.17B (+29.0%)
|
873.10M
est: 953.45M (-8.4%)
|
786.80M
est: 958.56M (-17.9%)
|
1.07B
est: 1.01B (+6.0%)
|
1.07B
1.05B – 1.13B
+5.7% YoY
|
1.17B
1.14B – 1.22B
+9.5% YoY
|
1.29B
1.29B – 1.29B
+9.9% YoY
|
1.41B
1.38B – 1.47B
+9.4% YoY
|
1.54B
1.51B – 1.62B
+9.5% YoY
|
| EBIT |
182.34M
est: 217.05M (-16.0%)
|
213.64M
est: 252.88M (-15.5%)
|
215.74M
est: 273.60M (-21.1%)
|
285.21M
est: 304.12M (-6.2%)
|
318.94M
est: 352.37M (-9.5%)
|
447.02M
est: 448.04M (-0.2%)
|
713.95M
est: 660.28M (+8.1%)
|
1.22B
est: 804.59M (+51.2%)
|
531.60M
est: 633.97M (-16.1%)
|
370.90M
est: 637.37M (-41.8%)
|
651.40M
est: 672.05M (-3.1%)
|
710.28M
698.69M – 749.88M
+5.7% YoY
|
777.45M
756.60M – 810.17M
+9.5% YoY
|
854.80M
854.54M – 855.06M
+9.9% YoY
|
935.26M
914.86M – 980.72M
+9.4% YoY
|
1.02B
1.00B – 1.07B
+9.5% YoY
|
| Net Income |
126.30M
est: 109.37M (+15.5%)
|
102.93M
est: 133.10M (-22.7%)
|
114.73M
est: 133.81M (-14.3%)
|
141.34M
est: 164.02M (-13.8%)
|
218.74M
est: 205.80M (+6.3%)
|
321.47M
est: 288.38M (+11.5%)
|
426.98M
est: 499.32M (-14.5%)
|
913.10M
est: 656.14M (+39.2%)
|
205.20M
est: 78.00M (+163.1%)
|
84.00M
est: 280.52M (-70.1%)
|
154.90M
est: 340.46M (-54.5%)
|
371.50M
350.63M – 392.37M
+9.1% YoY
|
444.72M
408.10M – 481.34M
+19.7% YoY
|
541.29M
432.27M – 650.32M
+21.7% YoY
|
621.55M
603.93M – 660.83M
+14.8% YoY
|
724.71M
704.16M – 770.50M
+16.6% YoY
|
| SGA |
291.63M
est: 261.04M (+11.7%)
|
331.32M
est: 304.14M (+8.9%)
|
380.13M
est: 329.05M (+15.5%)
|
424.07M
est: 365.76M (+15.9%)
|
476.89M
est: 423.79M (+12.5%)
|
564.66M
est: 538.85M (+4.8%)
|
745.72M
est: 794.09M (-6.1%)
|
829.00M
est: 967.65M (-14.3%)
|
848.70M
est: 772.08M (+9.9%)
|
884.00M
est: 776.22M (+13.9%)
|
811.40M
est: 818.46M (-0.9%)
|
865.02M
850.89M – 913.24M
+5.7% YoY
|
946.81M
921.42M – 986.66M
+9.5% YoY
|
1.04B
1.04B – 1.04B
+9.9% YoY
|
1.14B
1.11B – 1.19B
+9.4% YoY
|
1.25B
1.22B – 1.31B
+9.5% YoY
|
| EPS |
1.85
est: 1.59 (+16.7%)
|
1.50
est: 1.93 (-22.3%)
|
1.67
est: 1.94 (-13.9%)
|
2.07
est: 2.38 (-13.0%)
|
3.20
est: 2.98 (+7.3%)
|
4.70
est: 4.18 (+12.4%)
|
6.24
est: 7.24 (-13.8%)
|
13.35
est: 9.51 (+40.3%)
|
3.00
est: 1.13 (+165.5%)
|
1.22
est: 3.99 (-69.4%)
|
2.24
est: 4.91 (-54.4%)
|
5.39
5.08 – 5.68
+9.9% YoY
|
6.45
5.91 – 6.97
+19.5% YoY
|
7.67
6.26 – 9.42
+18.9% YoY
|
9.00
8.75 – 9.57
+17.4% YoY
|
10.50
10.20 – 11.16
+16.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rene Faber | Head of Bioprocess Solutions Division & Member of Executive Board | 1M | — |
| Florian Funck | Chief Financial Officer & Member of Executive Board | 1M | — |
| Alexandra Gatzemeyer | Head of the Lab Products & Services Division and Member of Executive Board | 1M | — |
| Michael Grosse | Chief Executive Officer & Chairman of the Executive Board | 1M | — |
| Ralf Mohrschladt | Physicist & Head of Supply Chain Management - Germany | — | — |
| Theo Thijssen | President of Environmental Technology Division | — | — |
| Maurice Phelan | President of Sartorius North America | — | male |
| Patricia Spannagel | Head of Quality Assurance - Mechatronics Division Goettingen | — | female |
| Petra Muller | Head of Investor Relations | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SRT3.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
